Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer [0.03%]
同源重组修复基因异常与转移性激素敏感性前列腺癌患者预后之间的关系研究
Chadi Hage Chehade,Ryon P Graf,Zeynep Irem Ozay et al.
Chadi Hage Chehade et al.
However, there are limited data regarding their association with outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial [0.03%]
初始转移性前列腺癌联合细胞减灭术、放疗或消融的IP2-ATLANTA内部预试验二期随机对照试验
Martin J Connor,Taimur T Shah,Johanna Sukumar et al.
Martin J Connor et al.
Background and objective: Cytoreduction of the primary prostate cancer, involved lymph nodes, and metastases may confer improved cancer control in de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC).
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer [0.03%]
寡转移前列腺癌的转移灶导向治疗辩论会三期
Maneesh Singh,Vedang Murthy,Piet Ost
Maneesh Singh
Oligometastatic prostate cancer (OMPC), characterized by limited metastatic burden (≤5 lesions), encompasses 3 major subtypes: de novo synchronous oligometastatic hormone-sensitive prostate cancer (om-HSPC), metachronous oligorecurrent HSPC (or-HSPC), and oligoprogressive castrate-resistant prostate
Variation in Intramuscular Fat Deposition of Goats and Sheep and Its Correlation with Gut Microbiota [0.03%]
肉中脂肪沉积的差异及与肠道微生物的相关性研究
Lei Yang,Shaobin Li,Jiagong Hou et al.
Lei Yang et al.
The content of fatty acid synthase (FAS) in the duodenum of the goats was lower, but the content of hormone-sensitive lipase (HSL) in both the pancreas and duodenum was greater (p < 0.05).
Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting [0.03%]
将侵袭性前列腺癌相关抑癌基因状态与临床变量相结合，以精确诊断预后并预测转移性激素敏感设置下雄激素受体途径抑制剂的反应
Martino Pedrani,Giuseppe Salfi,Sara Merler et al.
Martino Pedrani et al.
However, their prognostic and predictive role in metastatic hormone-sensitive prostate cancer (mHSPC) is unclear.
Chuyang Wei,Ruitao Cai,Yingte Song et al.
Chuyang Wei et al.
Nattokinase (NK) is a serine protease with stable enzyme activity and good freeze-thaw tolerance, which exerts lipid-lowering and anti-atherosclerotic effects by activating hormone-sensitive lipase (HSL), inhibiting hydroxymethylglutaryl monoacyl coenzyme A reductase (HMG-CoA reductase), and enhancing
Heterocyclic androstane derivatives targeting hormone-related cancers: Synthesis, bioactivity and docking studies [0.03%]
targeting激素相关癌症的杂环雄甾烷衍生物：合成、生物活性及对接研究
Tijana Lj Šestić,Sofija S Bekić,Maja A Marinović et al.
Tijana Lj Šestić et al.
Their cytotoxicity was tested against five cancer cell lines: breast adenocarcinoma cells (MCF7), acute lymphoblastic leukemia (CCRF-CEM), cervical carcinoma cells (HeLa), hormone-independent (DU 145) and hormone-sensitive prostate cancer cells (LNCaP), as well as against normal skin fibroblasts (BJ)
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov's model-based evaluation [0.03%]
瑞醋鲁胺对比比卡鲁胺及激素剥夺治疗高容量、转移性、雄激素敏感型前列腺癌的成本效益分析：基于马尔可夫模型的评估
Juan Hong,Xiaohui Zeng,Wenjun Chen et al.
Juan Hong et al.
Objectives: Rezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines [0.03%]
转移性去势抵抗性前列腺癌一线和后续治疗的系统疗法贝叶斯网络meta分析
Marie Wosny,Stefanie Aeppli,Stefanie Fischer et al.
Marie Wosny et al.
castration-resistant prostate cancer (mCRPC) presents a challenge for clinicians in determining the optimal treatment sequence because of the lack of direct head-to-head comparisons, which is further complicated by the now-widespread use of androgen receptor pathway inhibitors (ARPIs) in metastatic hormone-sensitive
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment [0.03%]
美国食品药品监督管理局批准的抗癌疗法的再利用：探索低级别浆液性卵巢癌治疗中的内分泌和靶向途径
Vivek Podder,Rachel N Grisham,Robert L Coleman et al.
Vivek Podder et al.
These efforts may help expand National Comprehensive Cancer Network-endorsed options, and provide new hope for patients with hormone-sensitive low-grade serous ovarian cancer.
耗时 0.11916 秒，为您在
48229835
条记录里面共找到 4899 篇文章 [XML]